Literature DB >> 18490101

siRNA-mediated Erc gene silencing suppresses tumor growth in Tsc2 mutant renal carcinoma model.

Osamu Imamura1, Hiroaki Okada, Yuuki Takashima, Danqing Zhang, Toshiyuki Kobayashi, Okio Hino.   

Abstract

Silencing of gene expression by small interfering RNAs (siRNAs) is rapidly becoming a powerful tool for genetic analysis and represents a potential strategy for therapeutic product development. However, there are no reports of systemic delivery of siRNAs for stable treatment except short hairpin RNAs (shRNAs). On the other hand, there are many reports of systemic delivery of siRNAs for transient treatment using liposome carriers and others. With regard to shRNAs, a report showed fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Therefore, we decided to use original siRNA microspheres instead of shRNA for stable treatment of disease. In this study, we designed rat-specific siRNA sequences for Erc/mesothelin, which is a tumor-specific gene expressed in the Eker (Tsc2 mutant) rat model of hereditary renal cancer and confirmed the efficacy of gene silencing in vitro. Then, by using siRNA microspheres, we found that the suppression of Erc/mesothelin caused growth inhibition of Tsc2 mutant renal carcinoma cells in tumor implantation experiments in mice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490101     DOI: 10.1016/j.canlet.2008.04.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

2.  Toward personalized cancer nanomedicine - past, present, and future.

Authors:  Alexander H Stegh
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

3.  MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Authors:  Ombretta Melaiu; Justin Stebbing; Ylenia Lombardo; Elisa Bracci; Norihisa Uehara; Alessandra Bonotti; Alfonso Cristaudo; Rudy Foddis; Luciano Mutti; Roberto Barale; Federica Gemignani; Georgios Giamas; Stefano Landi
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

4.  Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer.

Authors:  Emmanuel Zervos; Steven Agle; Andrew G Freistaedter; Gwendolyn J B Jones; Rachel L Roper
Journal:  J Exp Clin Cancer Res       Date:  2016-03-01

5.  Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

Authors:  Michael White; Andrew Freistaedter; Gwendolyn J B Jones; Emmanuel Zervos; Rachel L Roper
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.